3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Small Cell Lung Carcinoma
15
Lung Neoplasms
5
Neoplasms
4
Sarcoma
3
Sarcoma, Ewing
2
Neuroendocrine Tumors
2
Desmoplastic Small Round Cell Tumor
2
Stomach Neoplasms
1
SCLC, Extensive Stage
1
Platinum-Resistant Lung Small Cell Carcinoma
1
Ovarian Neoplasms
1
Neutropenia
1
Mesothelioma
1
Leiomyosarcoma
1
Glioblastoma
1
Gastrointestinal Malignancies
1
Gastro-enteropancreatic neuroendocrine tumor
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Adenoma, Islet Cell
1
Interventions
Doxorubicin
6
Specimen Handling
5
Radiotherapy
3
Radiation
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Biopsy
3
pembrolizumab
2
liposomal doxorubicin
2
eribulin
2
Ifosfamide
2
toripalimab
1
talimogene laherparepvec
1
rucaparib
1
ribociclib
1
regorafenib
1
peposertib
1
pazopanib
1
olaratumab
1
olaparib
1
lenvatinib
1
futibatinib
1
durvalumab
1
dinutuximab
1
cemiplimab
1
cediranib
1
cabozantinib
1
avelumab
1
anlotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leiomyosarcoma
×
PM 01183
×
1 year
×
Clear all
NCT06088290
2026-05-15
SaLuDo
PharmaMar
Phase 3
Active not recruiting
455 enrolled